冲击波碎石与输尿管镜治疗输尿管结石的多中心随机对照非劣效性试验(TISU)
TISU 是一项多中心随机对照非劣效性试验,比较最多两次冲击波碎石(SWL)与输尿管镜(URS)作为输尿管结石初始治疗的效果。共随机 613 例患者(SWL 306 例,URS 307 例),SWL 组 22.1% 需进一步治疗,URS 组 10.3%,绝对风险差 11.7%(95%CI 5.6%, 17.8%),在预设 20% 非劣效界值内,证实 SWL 非劣于 URS;但 URS 总体临床结局更优,SWL 在医疗成本方面结果更好。
要点
- SWL 非劣于 URS:需进一步治疗的风险差 11.7%(95%CI 5.6%, 17.8%),低于 20% 界值。
- URS 结石清除相关再干预率更低(10.3% vs 22.1%)。
- SWL 为门诊无创治疗,医疗成本方面结果更好。
核心结论
- 本随机对照试验旨在检验 SWL 是否非劣于 URS,结果证实非劣效性成立。
- 尽管 SWL 为门诊无创治疗且对患者和减少住院资源利用有潜在优势,但试验显示 URS 相比 SWL 在总体临床结局上有获益,反映当代实践。
研究设计与样本
- 多中心随机对照非劣效性试验,比较最多两次 SWL 与 URS 作为需干预输尿管结石的初始治疗。
- 2013 年 7 月 1 日至 2017 年 6 月 30 日招募,从 1291 例合格患者中纳入 613 例,随机分配 SWL 组 306 例、URS 组 307 例。
- 纳入标准为年龄超过 16 岁、单发输尿管结石且临床认为需要干预者;计划意向性治疗和符合方案分析。
主要发现
- 绝对风险差为 11.7%(95%CI 5.6%, 17.8%),有利于 URS,但在预设 20% 非劣效界值内。
- 次要结局包括生活质量评估、疼痛严重程度和严重并发症,基于基线、8 周和 6 个月问卷。
关键数值与推荐
- 非劣效界值设为 20%。
- SWL 组需进一步治疗比例 22.1%,URS 组 10.3%,绝对风险差 11.7%(95%CI 5.6%, 17.8%)。
临床怎么用
- TISU 研究为这一常见健康问题的治疗方式选择提供了新证据,有助于指导临床路径。
- 患者和医疗提供者可据此优化该常见泌尿系统疾病的治疗路径。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal stone disease is common and can cause emergency presentation with acute pain due to ureteric colic. International guidelines have stated the need for a multicentre randomised controlled trial (RCT) to determine whether a non-invasive outpatient (shockwave lithotripsy [SWL]) or surgical (ureteroscopy [URS]) intervention should be the first-line treatment for those needing active intervention. This has implications for shaping clinical pathways. OBJECTIVE: To report a pragmatic multicentre non-inferiority RCT comparing SWL with URS. DESIGN, SETTING, AND PARTICIPANTS: This trial tested for non-inferiority of up to two sessions of SWL compared with URS as initial treatment for ureteric stones requiring intervention. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was whether further intervention was required to clear the stone, and secondary outcomes included quality of life assessment, severity of pain, and serious complications; these were based on questionnaires at baseline, 8 wk, and 6 mo. We included patients over 16 yr with a single ureteric stone clinically deemed to require intervention. Intention-to-treat and per-protocol analyses were planned. RESULTS AND LIMITATIONS: The study recruited between July 1, 2013 and June 30, 2017. We recruited 613 participants from a total of 1291 eligible patients, randomising 306 to SWL and 307 to URS. Sixty-seven patients (22.1%) in the SWL arm needed further treatment compared with 31 patients (10.3%) in the URS arm. The absolute risk difference was 11.7% (95% confidence interval 5.6%, 17.8%) in favour of URS, which was inside the 20% threshold we set for demonstrating noninferiority of SWL. CONCLUSIONS: This RCT was designed to test whether SWL is non-inferior to URS and confirmed this; although SWL is an outpatient noninvasive treatment with potential advantages both for patients and for reducing the use of inpatient health care resources, the trial showed a benefit in overall clinical outcomes with URS compared with SWL, reflecting contemporary practice. The Therapeutic Interventions for Stones of the Ureter (TISU) study provides new evidence to help guide the choice of modality for this common health condition. PATIENT SUMMARY: We present the largest trial comparing ureteroscopy versus extracorporeal shockwave lithotripsy for ureteric stones. While ureteroscopy had marginally improved outcome in terms of stone clearance, as expected, shockwave lithotripsy had better results in terms of health care costs. These results should enable patients and health care providers to optimise treatment pathways for this common urological condition.
引用
- Dasgupta R, Cameron S, Aucott L, et al. Shockwave Lithotripsy Versus Ureteroscopic Treatment as Therapeutic Interventions for Stones of the Ureter (TISU): A Multicentre Randomised Controlled Non-inferiority Trial. Eur Urol. 2021. PMID: 33810921. doi:10.1016/j.eururo.2021.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。